NAMS NewAmsterdam Pharma Company N.V. Ordinary Shares
XNAS
18.21
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
NAMS
$18.21
—
What changed
Recent filings, trades and movesKey stats
$18.21
- 52-Week Range
- $17.90 – $42.20
- YTD
- -48.26%
- IV Rank (30D)
- 73.16
- Straddle Price
- $3.85
- P/C Vol Ratio
- 3.94
- Market Cap
- $2.3B
- Open
- $19.08
- Day Range
- $17.90 – $19.14
- Volume
- 939,171
- Prev Close
- $18.90
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 1.26 |
| Cost of Equity (CAPM) | 11.85% (VRP-adj) |
| WACC | 11.91% |
| Volatility Risk Premium | +73.2pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.2B |
| Return on Equity (TTM) | -32.5% |
| Book / Price | 26.9% |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -581.6% |
| Debt / Equity | 0.00 |
| Quality Score | 3/6 — normal (10y DCF) |
| SMA 50 | $22.10 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $20.34 |
| Bollinger Width / SMA20 | 15.7% (drives anchor stability) |
| Net Debt | $-0.4B |
| Market Cap | $2B |
Peers used for multiples: APGE, CGON, CRNX, DNTH, NTRA, ORKA, RVMD, XENE
60-Day Conviction
79%
20-Day Fair Value
≈ by Dec 8, 2026
$18.29
α +0.5%
rank 87%
conviction
39%
40-Day Fair Value
≈ by Jan 6, 2027
$18.97
α +4.3%
rank 85%
conviction
92%
60-Day Fair Value
≈ by Feb 4, 2027
$18.87
α +3.8%
rank 75%
conviction
79%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $33.69 | 14% | median 6.6× · 8 peers |
| Peer P/S | $49.14 | 14% | median 213.8× · 5 peers |
| Market Anchor (SMA50) | $22.10 | 52% | stability 72% (BB-width) |
| Options Expected (B-L 30d) | $18.55 | 20% | 11 strikes · skew +0.20 |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $2.3B
- Employees
- 100
- List Date
- 2022-11-23
- CIK
- 0001936258
- Last Earnings
- Aug 5 before open · −0.5% vs ±18.9% expected
- Headquarters
- Narrden, P7
- Homepage
- https://www.newamsterdampharma.com
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|
| Jan | -- | 19.42% | 71.30% | -14.14% | -11.59% | 16.25% |
| Feb | -- | 2.92% | 9.81% | -1.69% | 12.32% | 5.84% |
| Mar | -- | 2.16% | 0.47% | 0.99% | -2.50% | 0.28% |
| Apr | -- | 5.17% | 2.06% | 4.08% | -12.95% | -0.41% |
| May | -- | -5.52% | -14.66% | -9.59% | 18.47% | -2.83% |
| Jun | -- | -13.78% | 1.53% | -4.33% | 6.61% | -2.49% |
| Jul | -- | -4.00% | -16.81% | 19.70% | -19.66% | -5.19% |
| Aug | -- | -8.76% | -4.84% | 13.02% | -7.82% | -2.10% |
| Sep | -- | -11.31% | 4.34% | 15.47% | -2.41% | 1.52% |
| Oct | -- | 6.89% | -1.56% | 29.26% | -16.97% | 4.41% |
| Nov | -21.74% | 5.40% | 11.39% | 11.62% | -7.26%* | -0.12% |
| Dec | 23.16% | 15.27% | 30.86% | -11.44% | -- | 14.46% |
| Total | -3.61% | 8.52% | 98.08% | 53.18% | -40.76% | 23.08% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $20.19
SMA 50: $21.95
SMA 200: $29.39
Current: $18.22
EMA 12: $19.76
EMA 26: $20.66
MACD: -0.8936 | Signal: -0.0836
BEARISH
ADX (14): 21.10
WEAK TREND
+DI: 19.71
−DI: 26.53
Momentum Oscillators
RSI (14): 35.40
NEUTRAL
Stoch %K: 6.24
Stoch %D: 18.81
Williams %R: -92.71
Volume & Volatility
BB Upper: $21.97
BB Lower: $18.40
OVERSOLD
OBV: 18,081,231
Vol SMA 20: 1,518,786
Vol ROC: -41.21%
ATR: $1.32
True Range: $1.25
HV 20: 68.6%
HV 30: 58.7%
HV 60: 56.2%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL (confidence level 6/10)
Key Drivers and Primary Risks:
- Bullish momentum from recent earnings beat
- Bearish technical signals from MACD and Stochastic indicators
- High volatility and implied volatility premium
Investment Thesis: NAMS presents a mixed bag, with short-term bearish signals contrasting medium-term bullish trends. The company's recent earnings beat has boosted investor sentiment, but the options market suggests a higher probability of a downside move in the near term.
Recent News Sentiment Impact: Positive news headlines from NAMS' upcoming presentations and investor conferences have contributed to the stock's recent price action.
Technical Analysis
Trend Direction: Short-term: BEARISH (MACD bearish crossover, Stochastic oversold) Medium-term: BULLISH (SMA 50 above SMA 20) Long-term: NEUTRAL (no clear trend)
Support/Resistance Levels:
- Lower band: $25.42
- Middle band: $27.16
- Upper band: $28.89
Momentum Signals: RSI interpretation: Neutral (31.86), not oversold or overbought MACD signal: Bearish (crossover below signal line) Bollinger Bands position: Oversold, with potential for mean reversion
Volume Analysis: Volume rate of change is negative (-75.81%), suggesting institutional selling.
News & Sentiment Analysis
Recent Headlines Summary: NAMS has announced upcoming presentations and investor conferences, which have been well-received by the market.
Sentiment Assessment: Positive (aggregate sentiment from recent news headlines)
Catalyst Identification: Upcoming investor conferences and presentations in June
Market Narrative: The market narrative is focused on NAMS' potential for future growth, with investors awaiting further catalysts.
Risk & Volatility Assessment
Beta Interpretation: High risk relative to the broader market (beta 1.05)
Volatility Regime: Above average volatility - stock moves with market amplification
Options Market Signals: Implied volatility premium is high (234.4%), indicating a higher probability of larger price movements.
Downside Protection: Support levels are present at $25.42 and $27.16, but the options market suggests a higher risk of a downside move in the near term.
Market Context & Positioning
Sector Performance: NAMS is outperforming its sector peers in terms of revenue growth (49% YoY).
Institutional Activity: Institutional interest is mixed, with some investors selling and others buying.
Correlation Analysis: The stock's correlation with the market is moderate (0.24), indicating a mix of independent and correlated movements.
Relative Valuation: NAMS is positioned within its trading range, with potential for mean reversion or breakout.
Key Levels & Action Items
Critical Price Levels:
- Support level 1: $25.42
- Resistance level 1: $28.89
- Critical price level: $27.16 (SMA 50)
Breakout/Breakdown Levels: No clear levels, but the options market suggests a higher risk of a downside move in the near term.
Time-Sensitive Catalysts: Earnings reports and investor conferences in June
Risk Management: Stop-loss levels can be set at $24.60 (2% below current price) or $26.80 (4% above current price). Position sizing should consider the stock's high volatility and risk relative to the broader market.
This comprehensive analysis provides a detailed framework for understanding NAMS' technical, fundamental, and market-related factors. By acknowledging both bullish and bearish signals, investors can make more informed decisions regarding this high-risk, high-reward stock.
Generated
News
All NAMS news →
Earnings History
9 of 10 under expected move
Avg Expected Move
19.20%
Avg Actual Move
4.33%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-05-09 | After-Close | 16.01% | 1.97% | 0.12x | Within |
| 2024-08-07 | After-Close | 31.93% | 7.98% | 0.25x | Within |
| 2024-11-06 | After-Close | 35.12% | 3.95% | 0.11x | Within |
| 2025-02-26 | After-Close | 15.35% | 6.09% | 0.40x | Within |
| 2025-05-08 | After-Close | 19.20% | 4.67% | 0.24x | Within |
| 2025-08-06 | After-Close | 19.79% | 2.79% | 0.14x | Within |
| 2025-11-05 | After-Close | 21.90% | 2.82% | 0.13x | Within |
| 2026-02-18 | Pre-Market | 6.88% | 1.48% | 0.22x | Within |
| 2026-05-07 | After-Close | 6.96% | 11.13% | 1.60x | Exceeded |
| 2026-08-05 | Pre-Market | 18.87% | 0.47% | 0.02x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
NAMS Options Activity & IV Rank
NAMS IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 95.1%
7-DTE IV: 95.1%
Expected Move: $3.85
7-DTE Move: $3.35
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 529
Put Volume: 2,086
P/C Volume: 3.943
BEARISH
Call OI: 15,133
Put OI: 19,637
P/C OI: 1.298
Total OI: 34,770
ATM Options Pricing
ATM Call: $2.35
ATM Put: $1.50
Call %: 12.9%
Put %: 8.2%
Chain Summary
Chain Volume: 2,615
Chain OI: 34,770
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 57th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
57%
vs own history
GEX tilt
-0.16
OI-weighted, today
Vanna tilt
-0.29
δ-sensitivity to IV
Charm tilt
-0.15
δ-decay vs time
? What is this?
· 8 ATM contracts, 6k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)41.2MediumNov 9
IV Rank (30 DTE)73.2MediumNov 9
Straddle Price (30 DTE)$3.85Nov 9
Beta Analysis
Risk Metrics
Beta: 1.3783
Alpha: -73.76%
Correlation: 0.3526
R-Squared: 12.4%
Stock Volatility: 53.9%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own NAMS
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Viking Global Hedge fund Andreas Halvorsen | $142.5M | #60 of 90 | 0.0% | 13F | |
| Duquesne Family Office Family office Stanley Druckenmiller | $104.0M | #15 of 86 | 0.0% | 13F | |
| Citadel Hedge fund Ken Griffin | $21.9M | #1093 of 6285 | -9.3% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $17.0M | #1223 of 3716 | +65.1% | 13F | |
| Point72 Hedge fund Steve Cohen | $5.7M | #938 of 1945 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
NAMS Institutional Ownership (13F)
Filings for 2026-06-30 · 52 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 122,309,518 (as of 2026-09-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
8 filers$10.38M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $5.02M | 48.32% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $1.30M | 12.54% | 2026-06-30 |
| 3 | LMR Partners LLP | $1.16M | 11.13% | 2026-06-30 |
| 4 | Tidal Investments LLC | $671.02K | 6.46% | 2026-06-30 |
| 5 | Caption Management, LLC | $633.74K | 6.11% | 2026-06-30 |
| 6 | Point72 Asset Management, L.P. | $620.19K | 5.97% | 2026-06-30 |
| 7 | Goldman Sachs Group Inc Custodian | $576.13K | 5.55% | 2026-06-30 |
| 8 | Jane Street Group, LLC Custodian | $406.68K | 3.92% | 2026-06-30 |
9 filers$59.01M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $19.27M | 32.66% | 2026-06-30 |
| 2 | PERCEPTIVE ADVISORS LLC | $16.95M | 28.72% | 2026-06-30 |
| 3 | Jefferies Financial Group Inc. | $7.30M | 12.36% | 2026-09-30 |
| 4 | LMR Partners LLP | $7.27M | 12.32% | 2026-06-30 |
| 5 | BOOTHBAY FUND MANAGEMENT, LLC | $4.11M | 6.96% | 2026-06-30 |
| 6 | Caption Management, LLC | $3.12M | 5.30% | 2026-06-30 |
| 7 | Point72 Asset Management, L.P. | $620.19K | 1.05% | 2026-06-30 |
| 8 | Jane Street Group, LLC Custodian | $247.40K | 0.42% | 2026-06-30 |
| 9 | Wells Fargo & Company Custodian | $128.78K | 0.22% | 2026-06-30 |
NAMS Insider Trading (Form 4)
Latest: 2026-10-02Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Johannes Jacob Pieter Kastelein | Chief Scientific Officer | Mixed Sell −50,246 · Exer +50,246 |
— | $25.03 | -$1.26M | EDGAR |
| 2026-09-15 | Michael H. Davidson | Chief Executive Officer | Buy (P) | +10,000 | $22.65 | $226.5K | EDGAR |
| 2026-09-09 | John W Smither | Director | Sell (S) | −1,600 | $25.32 | -$40.5K | EDGAR |
| 2026-09-03 | Robert William Gunning | Vice President, Controller | Award (A) | +3,200 | — | EDGAR | |
| 2026-08-25 | Johannes Jacob Pieter Kastelein | Chief Scientific Officer | Mixed Exer +125,000 · Sell −125,000 |
— | $26.91 | -$3.36M | EDGAR |
| 2026-07-22 | Louise Frederika Kooij | Chief Accounting Officer | Mixed Sell −105,000 · Exer +105,000 |
— | $20.84 | -$1.99M | EDGAR |
| 2026-06-24 | Louise Frederika Kooij | Chief Accounting Officer | Mixed Exer +40,000 · Sell −40,000 |
— | $20.74 | -$757.2K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
NAMS Insider Holdings
5 insiders · @ $18.22
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Michael H. Davidson | Chief Executive Officer | 1,078,638 | $19.65M | $226.5K | 1 | 2026-09-15 |
| 2 | Johannes Jacob Pieter Kastelein | Chief Scientific Officer | 173,048 | $3.15M | -$4.62M | 2 | 2026-10-02 |
| 3 | Louise Frederika Kooij | Chief Accounting Officer | 24,353 | $443.7K | -$4.39M | 2 | 2026-07-22 |
| 4 | John W Smither | Director | 8,760 | $159.6K | -$40.5K | 1 | 2026-09-09 |
| 5 | Robert William Gunning | Vice President, Controller | 3,200 | $58.3K | $0 | 1 | 2026-09-03 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
NAMS Board & Officers
As of SEC filings through Oct 2, 2026Directors 9
- James N Topper · since Dec 29, 2023
- Johannes Jacob Pieter Kastelein · since Dec 29, 2023
- John W Smither · since Dec 29, 2023
- Kamp Hilde Johanna van der · since Dec 29, 2023
- Louis G Lange · since Dec 29, 2023
- Michael H. Davidson · since Dec 29, 2023
- William Lewis · since Jan 4, 2024
- Mark C. McKenna · since Jul 16, 2024
- Adele M. Gulfo · since Apr 15, 2025
Officers 7
- Michael H. Davidson · Chief Executive Officer · since Dec 29, 2023
- Robert William Gunning · Vice President, Controller · since Aug 10, 2026
- Mayur Ian Somaiya · Chief Financial Officer · since Dec 29, 2023
- Douglas F Kling · Chief Operating Officer · since Dec 29, 2023
- Johannes Jacob Pieter Kastelein · Chief Scientific Officer · since Dec 29, 2023
- Louise Frederika Kooij · Chief Accounting Officer · since Dec 29, 2023
- Michael F Marino III · Chief Legal Officer and Corporate Secretary · since May 27, 2025
Changes in the last 10 years (54)
| Aug 10, 2026 | Robert William Gunning became Vice President, Controller |
| May 27, 2025 | Michael F Marino III became Chief Legal Officer and Corporate Secretary |
| Apr 15, 2025 | Adele M. Gulfo became a director |
| Jan 2, 2025 | Forbion IV Management B.V. reported in an SEC filing no longer being a 10% owner |
| Jan 2, 2025 | Forbion Growth Opportunities Fund I Cooperatief U.A. reported in an SEC filing no longer being a 10% owner |
| Jan 2, 2025 | Forbion Growth Management B.V. reported in an SEC filing no longer being a 10% owner |
| Jan 2, 2025 | Forbion Capital Fund IV Cooperatief U.A. reported in an SEC filing no longer being a 10% owner |
| Jan 2, 2025 | ForGrowth NAP B.V. reported in an SEC filing no longer being a 10% owner |
| Dec 17, 2024 | Bain Capital Life Sciences Investors, LLC reported in an SEC filing no longer being a 10% owner |
| Dec 17, 2024 | Bain Capital Life Sciences Investors II, LLC reported in an SEC filing no longer being a 10% owner |
| Dec 17, 2024 | Bain Capital Life Sciences III General Partner, LLC reported in an SEC filing no longer being a 10% owner |
| Dec 17, 2024 | Bain Capital Life Sciences Fund III, L.P. reported in an SEC filing no longer being a 10% owner |
| Dec 17, 2024 | Bain Capital Life Sciences Fund II, L.P. reported in an SEC filing no longer being a 10% owner |
| Dec 17, 2024 | BCLS II Investco, LP reported in an SEC filing no longer being a 10% owner |
| Dec 17, 2024 | BCLS II Investco (GP), LLC reported in an SEC filing no longer being a 10% owner |
| Dec 17, 2024 | BCLS Fund III Investments, LP reported in an SEC filing no longer being a 10% owner |
| Dec 17, 2024 | BCLS Fund III Investments GP, LLC reported in an SEC filing no longer being a 10% owner |
| Dec 17, 2024 | BCIP Life Sciences Associates, LP reported in an SEC filing no longer being a 10% owner |
| Jul 16, 2024 | Wouter Joustra became a director |
| Jul 16, 2024 | The company announced the departure of Hugo Alexander Slootweg from the board in an SEC filing |
| Jul 16, 2024 | Mark C. McKenna became a director |
| Apr 25, 2024 | William A Jones Jr became Chief Commercial Officer |
| Apr 2, 2024 | Juliette Berangere Audet first listed as Chief Business Officer in an SEC filing |
| Mar 28, 2024 | The company announced the departure of Juliette Berangere Audet from the board in an SEC filing |
| Jan 4, 2024 | William Lewis became a director |
| Jan 1, 2024 | Forbion IV Management B.V. became a 10% owner |
| Jan 1, 2024 | Forbion Growth Opportunities Fund I Cooperatief U.A. became a 10% owner |
| Jan 1, 2024 | Forbion Growth Management B.V. became a 10% owner |
| Jan 1, 2024 | Forbion Capital Fund IV Cooperatief U.A. became a 10% owner |
| Jan 1, 2024 | ForGrowth NAP B.V. became a 10% owner |
| Dec 29, 2023 | Nicholas Downing became a director |
| Dec 29, 2023 | Michael H. Davidson became a director |
| Dec 29, 2023 | Michael H. Davidson became Chief Executive Officer |
| Dec 29, 2023 | Mayur Ian Somaiya became Chief Financial Officer |
| Dec 29, 2023 | Louise Frederika Kooij became Chief Accounting Officer |
| Dec 29, 2023 | Louis G Lange became a director |
| Dec 29, 2023 | Kamp Hilde Johanna van der became a director |
| Dec 29, 2023 | Juliette Berangere Audet became a director |
| Dec 29, 2023 | John W Smither became a director |
| Dec 29, 2023 | Johannes Jacob Pieter Kastelein became a director |
| Dec 29, 2023 | Johannes Jacob Pieter Kastelein became Chief Scientific Officer |
| Dec 29, 2023 | James N Topper became a director |
| Dec 29, 2023 | Hugo Alexander Slootweg became a director |
| Dec 29, 2023 | Douglas F Kling became Chief Operating Officer |
| Dec 29, 2023 | Bain Capital Life Sciences Investors, LLC became a 10% owner |
| Dec 29, 2023 | Bain Capital Life Sciences Investors II, LLC became a 10% owner |
| Dec 29, 2023 | Bain Capital Life Sciences III General Partner, LLC became a 10% owner |
| Dec 29, 2023 | Bain Capital Life Sciences Fund III, L.P. became a 10% owner |
| Dec 29, 2023 | Bain Capital Life Sciences Fund II, L.P. became a 10% owner |
| Dec 29, 2023 | BCLS II Investco, LP became a 10% owner |
| Dec 29, 2023 | BCLS II Investco (GP), LLC became a 10% owner |
| Dec 29, 2023 | BCLS Fund III Investments, LP became a 10% owner |
| Dec 29, 2023 | BCLS Fund III Investments GP, LLC became a 10% owner |
| Dec 29, 2023 | BCIP Life Sciences Associates, LP became a 10% owner |
Not reported recently (4)
- Juliette Berangere Audet · Last reported as Chief Business Officer in an SEC filing dated May 2, 2025
- William A Jones Jr · Last reported as Chief Commercial Officer in an SEC filing dated Jan 7, 2025
- Wouter Joustra · Last reported as a director in an SEC filing dated Jul 19, 2024
- Nicholas Downing · Last reported as a director in an SEC filing dated Dec 29, 2023
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
NAMS Proposed Insider Sales (Form 144)
Latest: 2026-08-25
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
1 filing
· $7.0M notice value
· 1 unique filer
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Kastelein Johannes Jacob Pieter (1, $7.0M)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-25 144/A | Kastelein Johannes Jacob Pieter | Affiliate | 250,000 | $6.97M | 2026-08-25 | J.P. Morgan Securities LLC | 10b5-1 | EDGAR |
| 2026-05-26 | Louise Kooij | Officer | 210,000 | $7.44M | 2026-05-26 | J.P. Morgan Securities LLC | 10b5-1 | EDGAR |
| 2026-03-11 | Louis G. Lange | Affiliate | 44,619 | $1.40M | 2026-03-11 | J.P. Morgan Securities LLC | — | EDGAR |
| 2026-03-06 | Louis G. Lange | Affiliate | 28,186 | $878.8K | 2026-03-06 | J.P. Morgan Securities LLC | 10b5-1 | EDGAR |
| 2026-03-05 | Kastelein Johannes Jacob Pieter | Affiliate | 300,000 | $9.35M | 2026-03-02 | J.P. Morgan Securities LLC | 10b5-1 | EDGAR |
| 2026-03-02 | Michael H. Davidson | Affiliate | 443,707 | $15.73M | 2026-03-02 | J.P. Morgan Securities LLC | — | EDGAR |
| 2026-02-24 | Michael H. Davidson | Affiliate | 750,000 | $27.13M | 2026-02-24 | J.P. Morgan Securities LLC | 10b5-1 | EDGAR |
| 2026-02-20 | Kastelein Johannes Jacob Pieter | Officer, Director | 45,481 | $1.58M | 2026-02-20 | ABN AMRO | — | EDGAR |
| 2026-01-20 | Mayur Somaiya | Affiliate | 200,000 | $6.33M | 2026-01-20 | J.P. Morgan Securities LLC | 10b5-1 | EDGAR |
| 2026-01-07 | Michael Davidson | affiliate | 11,582 | $410.9K | 2026-01-07 | J.P. Morgan Securities LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-04
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-11-04 | Financial statements and exhibits | EDGAR |
| 2026-09-29 | Other events | EDGAR |
| 2026-09-21 | Other events | EDGAR |
| 2026-08-14 | Director or officer change | EDGAR |
| 2026-08-05 | Earnings results | EDGAR |
| 2026-07-24 | Other events | EDGAR |
| 2026-07-22 | Director or officer change | EDGAR |
| 2026-06-03 | Director or officer change · Shareholder vote results | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
14 ETFs hold NAMS
14 shown · $37.78M total exposure · 0.09% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | CGMM Capital Group U.S. Small and Mid Cap ETF | Capitalgroup | 0.42% | $14.7M | $3.5B | 2026-11-05 |
| 2 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.10% | $11.1M | $11.1B | 2026-11-06 |
| 3 | VHT Vanguard Health Care ETF | Vanguard | 0.02% | $4.8M | — | 2026-09-30 |
| 4 | SBIO ALPS Medical Breakthroughs ETF | Nport | 1.52% | $3.7M | — | 2026-08-31 |
| 5 | ESML iShares ESG Aware MSCI USA Small-Cap ETF | iShares (BlackRock) | 0.04% | $944,773 | $2.7B | 2026-11-06 |
| 6 | ONEQ Fidelity Nasdaq Composite Index ETF | Fidelity | 0.01% | $660,621 | $10.0B | 2026-11-05 |
| 7 | FHLC Fidelity MSCI Health Care Index ETF | Fidelity | 0.02% | $630,567 | $4.0B | 2026-11-05 |
| 8 | GURU Global X Guru Index ETF | Global X | 1.03% | $573,142 | — | 2026-11-06 |
| 9 | FMED Fidelity Disruptive Medicine ETF | Fidelity | 0.65% | $308,587 | $47.4M | 2026-11-05 |
| 10 | IBBQ Invesco Nasdaq Biotechnology ETF | Invesco | 0.15% | $176,338 | — | 2026-11-05 |
| 11 | ACSG American Century Small Cap Growth Insights ETF | Nport | 0.22% | $110,710 | — | 2026-08-31 |
| 12 | WSML iShares MSCI World Small-Cap ETF | iShares (BlackRock) | 0.01% | $71,990 | $656.6M | 2026-11-06 |
| 13 | MSML iShares MSCI USA Small-Cap ETF | iShares (BlackRock) | 0.02% | $51,748 | $271.8M | 2026-11-06 |
| 14 | TNXT T. Rowe Price Innovation Leaders ETF | Nport | 0.12% | $21,588 | — | 2026-06-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-1.68
TTM Revenue
$25.94M
TTM Net Income
$-204.89M
TTM Op. Cash Flow
$-150.47M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $19.16M | $-17.39M | $-0.14 | $-39.77M |
| Q2 '26 | 2026-06-30 | $3.70M | $-64.14M | $-0.52 | $-39.21M |
| Q4 '25 | 2025-12-31 | $32.00K | $-74.92M | $-0.63 | $-40.88M |
| Q3 '25 | 2025-09-30 | $348.00K | $-72.00M | $-0.61 | $-32.77M |
| Q2 '25 | 2025-06-30 | $19.14M | $-17.36M | $-0.15 | $-37.67M |
| Q1 '25 | 2025-03-31 | $2.98M | $-39.53M | $-0.34 | $-36.47M |
| Q4 '24 | 2024-12-31 | $12.77M | $-92.18M | $-1.05 | $-37.48M |
| Q3 '24 | 2024-09-30 | $29.11M | $-16.65M | $-0.18 | $-12.50M |
| Q2 '24 | 2024-06-30 | $2.28M | $-39.01M | $-0.41 | $-53.98M |
| Q1 '24 | 2024-03-31 | $1.40M | $-93.77M | $-1.06 | $-54.60M |
| Q4 '23 | 2023-12-31 | $803.00K | $-49.49M | $-0.60 | $-33.07M |
| Q3 '23 | 2023-09-30 | $2.94M | $-47.13M | $-0.57 | $-46.98M |
Q3 2026 • period ending 2026-09-30 • filed 2026-11-04
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
3.47
P/S
307.29
EV/EBITDA
—
EV/Sales
247.72
ROE
-41.1%
ROA
-36.8%
Div Yield
0.00%
FCF Yield
-6.56%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$2.19B
as of 2026-11-09
NAMS vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| NTRA Natera, Inc. Common Stock | $45.1B | — | +36.6% | +40.0% | 43 |
| RVMD Revolution Medicines, Inc. Common Stock | $41.6B | — | — | +151.5% | 66 |
| APGE Apogee Therapeutics, Inc. Common Stock | $10.2B | — | — | +78.2% | — |
| CRNX Crinetics Pharmaceuticals, Inc. | $9.0B | — | +2928.4% | +81.8% | — |
| ORKA Oruka Therapeutics, Inc. Common Stock | $6.8B | — | — | +272.3% | 5 |
| CGON CG Oncology, Inc. Common stock | $6.7B | — | +666.0% | +77.9% | 100 |
| DNTH Dianthus Therapeutics, Inc. Common Stock | $4.8B | — | −60.8% | +128.8% | 76 |
| XENE Xenon Pharmaceuticals Inc | $3.8B | — | — | −9.4% | 52 |
| NAMS NewAmsterdam Pharma Company N.V. Ordinar | $2.3B | — | −26.4% | −48.2% | 73 |
| Peer median | $7.9B | — | +351.3% | +80.0% | 59 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
14.11M
SI % of Float
16.36%
Days to Cover
10.64
Short Vol Ratio
48.1%
Free Float
86.23M
Float %
72.1%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-09-22